Martindale Pharma announces new additions to Tapclob range

Martindale Pharma has announced the addition of new product options to its Tapclob range of anxiety treatments.

The company has introduced an additional presentation to the range, providing a 250ml bottle for both the five mg/five ml and ten mg/five ml strengths, as well as the 150ml bottle. This will reduce the number of bottles needed for a significant number of patients.

Additionally, all packs of Tapclob will include a five ml oral syringe and a 30 ml dosing cup to make it easier than ever for patients and carers to accurately measure the required dose.

The UK's first licensed oral liquid suspension of clobazam, Tapclob is used to treat severe anxiety over a short time and other mental illnesses such as schizophrenia, as well as functioning as an antiepileptic drug for long-term treatment. It was launched in May 2013.

Michael Clark, chief marketing officer of Martindale Pharma, said: "This shows that Tapclob is continuing to adapt to the needs of both prescribers and patients alike in a therapeutic area where ease of use is really important."